Progress in research on neuroprotective mechanism of glucagon-like peptide-1 receptor agonists and analogues in Parkinson's disease
10.13200/j.cnki.cjb.000076
- VernacularTitle:胰高血糖素样肽-1受体激动剂及其类似物在帕金森病中神经保护作用机制的研究进展
- Author:
LI Xuefeng
- Publication Type:Journal Article
- Keywords:
Glucagon-like peptide-1 receptor agonist(GLP-1RA);
Parkinson's disease(PD);
Dopaminergic neurons;
Neuropro-tection
- From:
Chinese Journal of Biologicals
2023;36(12):1522-1529
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson's disease(PD)is the second common neurodegenerative disease that mostly occurs in middle-aged and elderly people. Currently,Levodopa is the main first-line treatment drug,but the long-term efficacy of patients is not good,and even side effects such as“on-off”phenomenon and orthostatic hypotension occur. Glucagon-like peptide-1receptor agonists(GLP-1RA)and analogues are endogenous peptide hormones that can be released into the blood and enter the central nervous system to exert neuroprotection by crossing the blood-brain barrier. Numerous studies have shown that GLP-1RA can improve movement disorders and restore dopaminergic neuron activity in PD. However,the mechanism of GLP-1RA is not yet fully clear. This paper summarized the mechanism of GLP-1RA and its analogues in improving PD movement disorders and restoring dopaminergic neuron activity,and reviewed the aspects of reducing neuroinflammation,inhibiting oxidative stress,inhibiting apoptosis,regulating mitochondrial morphology,increasing neuronal protrusions,enhancing autophagy,and regulating intestinal flora homeostasis,so as to provide new ideas for research of the mechanisms of PD and development of GLP-1RA-related new drugs.
